DNA polymerase θ (POLθ), repressed in somatic cells and overexpressed in several types of cancer, is crucial for DNA double-strand break repair during mitosis.
Simcere Zaiming Pharmaceutical Co. Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SIM-0508, a small-molecule inhibitor of DNA polymerase θ (POLθ), allowing initiation of clinical trials in locally advanced or metastatic solid tumors.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has identified thiadiazolyl derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Hangzhou Synrx Therapeutics Technology Co. Ltd. has divulged DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Breakpoint Therapeutics GmbH has nominated its first preclinical DNA damage response development candidate, BTX-011, for the treatment of solid tumors. IND-enabling activities have already commenced.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has described heterocyclic derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Hangzhou Synrx Therapeutics Technology Co. Ltd. has described heterocyclic compounds acting as DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.
